Kala Pharmaceuticals Inc (NASDAQ:KALA) Expected to Post Quarterly Sales of $2.92 Million
Wall Street brokerages predict that Kala Pharmaceuticals Inc (NASDAQ:KALA) will announce sales of $2.92 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from $2.20 million to $4.27 million. The business is expected to report its next quarterly earnings results on Monday, March 9th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full year sales of $7.81 million for the current fiscal year, with estimates ranging from $7.10 million to $9.17 million. For the next fiscal year, analysts expect that the company will post sales of $27.95 million, with estimates ranging from $17.16 million to $46.39 million. Zacks’ sales averages are an average based on a survey of research firms that cover Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.01). The company had revenue of $1.45 million for the quarter, compared to analyst estimates of $3.56 million.
A number of institutional investors have recently made changes to their positions in KALA. Bank of Montreal Can grew its stake in Kala Pharmaceuticals by 148.5% during the second quarter. Bank of Montreal Can now owns 4,014 shares of the company’s stock worth $26,000 after buying an additional 2,399 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Kala Pharmaceuticals by 17.1% during the second quarter. Parametric Portfolio Associates LLC now owns 39,692 shares of the company’s stock worth $253,000 after buying an additional 5,806 shares in the last quarter. Marshall Wace LLP acquired a new stake in Kala Pharmaceuticals during the first quarter worth about $325,000. Charles Schwab Investment Management Inc. grew its stake in Kala Pharmaceuticals by 34.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 51,405 shares of the company’s stock worth $328,000 after buying an additional 13,271 shares in the last quarter. Finally, Wedbush Securities Inc. grew its stake in Kala Pharmaceuticals by 163.9% during the third quarter. Wedbush Securities Inc. now owns 89,225 shares of the company’s stock worth $340,000 after buying an additional 55,410 shares in the last quarter. Hedge funds and other institutional investors own 67.24% of the company’s stock.
NASDAQ:KALA traded up $0.84 during mid-day trading on Tuesday, reaching $6.52. 1,216,149 shares of the company’s stock were exchanged, compared to its average volume of 777,858. Kala Pharmaceuticals has a one year low of $3.24 and a one year high of $9.25. The firm has a market capitalization of $196.21 million, a PE ratio of -2.26 and a beta of 2.16. The business’s fifty day simple moving average is $4.34 and its two-hundred day simple moving average is $4.44. The company has a debt-to-equity ratio of 1.65, a quick ratio of 5.94 and a current ratio of 6.25.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.
Featured Story: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.